Oric Pharmaceuticals, Inc. — Investor Relations & Filings
Filings indexed
390
across all filing types
Latest filing
2026-04-28
Proxy Solicitation & In…
Country
US
United States of America
Listing
US
ORIC
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer. The company's platform addresses the primary mechanisms of therapeutic resistance—innate, acquired, and bypass—with the goal of making existing treatments more effective and durable. Its pipeline includes several targeted therapeutics in clinical development. Key programs include enozertinib (ORIC-114), an inhibitor being studied in non-small cell lung cancer (NSCLC) with specific EGFR/HER2 mutations, and ORIC-944, which is in trials for prostate cancer. Oric employs a precision oncology approach, using biomarkers to identify patient populations most likely to respond to its treatments.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEF 14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer) | 2026-04-28 | English | |
| 4 - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-26 | English | |
| 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | |
| 10-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | |
| 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 38155746 | DEF 14A - Oric Pharmaceuticals, Inc. (0001796280) (Filer) | 2026-04-28 | English | ||
| 32898467 | 4 - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-26 | English | ||
| 32898472 | 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | ||
| 32898475 | 10-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | ||
| 32898468 | 8-K - ORIC PHARMACEUTICALS, INC. (0001796280) (Filer) | 2026-02-23 | English | ||
| 31755143 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 13223467 | Major Shareholding Notification 2026 | 2026-01-21 | English | ||
| 13223468 | Director's Dealing 2026 | 2026-01-21 | English | ||
| 13223469 | Regulatory Filings 2026 | 2026-01-16 | English | ||
| 13223470 | Regulatory Filings 2026 | 2026-01-16 | English | ||
| 13223471 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223472 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223473 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223474 | Director's Dealing 2026 | 2026-01-06 | English | ||
| 13223475 | Director's Dealing 2026 | 2026-01-06 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Oric Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32131/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32131 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32131 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32131 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32131}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Oric Pharmaceuticals, Inc. (id: 32131)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.